Description: X4 Pharmaceuticals, Inc., formerly Arsanis, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases including primary immunodeficiencies and cancer. The Company’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. Its product candidates include X4P-001, X4P-002 and X4P-003.
Home Page: www.x4pharma.com
XFOR Technical Analysis
61 North Beacon Street
Boston,
MA
02134
United States
Phone:
857 529 8300
Officers
| Name | Title |
|---|---|
| Dr. Paula Ragan Ph.D. | Founder, CEO, Pres, Sec. & Director |
| Mr. Adam S. Mostafa | CFO, Treasurer & Assistant Sec. |
| Dr. Murray W. Stewart M.D. | Interim Chief Medical Officer & Director |
| Dr. Richard Peters M.D., Ph.D. | Founder |
| Dr. Renato T. Skerlj Ph.D. | Founder |
| Dr. Keith T. Flaherty M.D. | Founder & Member of Corp. Advisory Board |
| Dr. Mary DiBiase Ph.D. | Chief Operating Officer |
| Dr. Arthur Taveras Ph.D. | Chief Scientific Officer |
| Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. | VP of Investor Relations & Corp. Communications |
| Dr. Robert David Arbeit | Sr. VP of Clinical Devel. and Translational Research |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0411 |
| Price-to-Sales TTM: | 53.8733 |
| IPO Date: | 2017-11-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 83 |